MRTX Mirati Therapeutics Inc

Price (delayed)

$68.16

Market cap

$3.78B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$11.94

Enterprise value

$3.53B

Mirati Therapeutics is a late-stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The ...

Highlights
The quick ratio is down by 36% year-on-year but it is up by 3.4% since the previous quarter
Mirati Therapeutics's net income has shrunk by 56% YoY and by 9% QoQ
The EPS fell by 39% YoY and by 7% QoQ

Key stats

What are the main financial stats of MRTX
Market
Shares outstanding
55.53M
Market cap
$3.78B
Enterprise value
$3.53B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.03
Price to sales (P/S)
51.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
48.43
Earnings
Revenue
$72.8M
EBIT
-$631.19M
EBITDA
-$629.08M
Free cash flow
-$448.68M
Per share
EPS
-$11.94
Free cash flow per share
-$8.09
Book value per share
$22.51
Revenue per share
$1.31
TBVPS
$25.62
Balance sheet
Total assets
$1.42B
Total liabilities
$172.02M
Debt
$45.83M
Equity
$1.25B
Working capital
$1.22B
Liquidity
Debt to equity
0.04
Current ratio
10.87
Quick ratio
10.73
Net debt/EBITDA
0.41
Margins
EBITDA margin
-864.1%
Gross margin
100%
Net margin
-871.5%
Operating margin
-858.5%
Efficiency
Return on assets
-45.2%
Return on equity
-52.2%
Return on invested capital
-63.3%
Return on capital employed
-48.6%
Return on sales
-867%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MRTX stock price

How has the Mirati Therapeutics stock price performed over time
Intraday
3.45%
1 week
23.93%
1 month
15.92%
1 year
-58.05%
YTD
-53.53%
QTD
-17.1%

Financial performance

How have Mirati Therapeutics's revenue and profit performed over time
Revenue
$72.8M
Gross profit
$72.8M
Operating income
-$624.98M
Net income
-$634.49M
Gross margin
100%
Net margin
-871.5%
The operating margin has soared by 73% YoY but it is down by 8% QoQ
Mirati Therapeutics's net margin has soared by 72% YoY but it has decreased by 8% from the previous quarter
Mirati Therapeutics's net income has shrunk by 56% YoY and by 9% QoQ
The company's operating income has shrunk by 52% YoY and by 9% QoQ

Growth

What is Mirati Therapeutics's growth rate over time

Valuation

What is Mirati Therapeutics stock price valuation
P/E
N/A
P/B
3.03
P/S
51.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
48.43
The EPS fell by 39% YoY and by 7% QoQ
MRTX's price to book (P/B) is 56% lower than its 5-year quarterly average of 6.9 and 51% lower than its last 4 quarters average of 6.2
MRTX's equity is down by 11% from the previous quarter
The price to sales (P/S) is 92% lower than the 5-year quarterly average of 637.4 and 78% lower than the last 4 quarters average of 231.4

Efficiency

How efficient is Mirati Therapeutics business performance
The ROS has soared by 72% YoY but it fell by 8% QoQ
The company's return on equity fell by 21% YoY and by 9% QoQ
Mirati Therapeutics's return on assets has decreased by 15% YoY and by 8% QoQ
MRTX's return on invested capital is down by 9% since the previous quarter but it is up by 3.8% year-on-year

Dividends

What is MRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRTX.

Financial health

How did Mirati Therapeutics financials performed over time
The total liabilities is up by 42% YoY but it is down by 10% QoQ
The quick ratio is down by 36% year-on-year but it is up by 3.4% since the previous quarter
Mirati Therapeutics's debt is 96% less than its equity
The debt to equity has grown by 33% from the previous quarter and by 33% YoY
MRTX's equity is down by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.